title: Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
abstract: OBJECTIVE
  What factors or attributes of a long-acting recombinant FSH (rFSH) or daily-administrated rFSH influence women's preferences IVF?
  
  
  CONCLUSIONS
  Patients' preferences for rFSH products are primary influenced by the attribute 'number of injections', but a low 'number of injections' is exchanged for a high 'number of injections' at a 6.2% decrease in 'risk of cycle cancellation due to low response' and at a 4.5% decrease in 'chance of OHSS'.
  
  
  BACKGROUND
  Injections of long-acting rFSH have been claimed to be preferred over daily-administrated rFSH injections, but patient preference studies to underpin this assumption have not been performed.
  
  
  METHODS
  A discrete choice experiment (DCE) was created to assess women's preference for long-acting or daily-administrated rFSH under varying attributes of efficiency, safety and burden. The selected attributes were the 'total number of injections', 'chance of ovarian hyperstimulation syndrome (OHSS)' and the 'risk of cycle cancellation due to low response'. Questionnaires were handed out during information gathering sessions in one academic hospital and two teaching hospitals in The Netherlands between April 2011 and April 2012.
  
  
  METHODS
  Women at the start of their first IVF treatment were asked to participate in this patient preference study. Participation was voluntary. We analysed the data by using mixed logit models to estimate the utility of each attribute.
  
  
  RESULTS
  Questionnaires (n = 125) were handed out with a response rate of 77% (97/125). Four respondents did not complete the questionnaire. Hence, there were 93 questionnaires available for analysis. All attributes significantly influenced women's preference. Overall, the lower 'number of injections' was preferred above the higher 'number of injections' (mean coefficient 1.25; P < 0.001), while an increase of 1% in 'chance of OHSS' or 5% 'risk of cycle cancellation due to low response' was non-preferred (mean coefficients -0.31 and -0.24, respectively, P < 0.01). The majority of respondents was willing to trade-off a lower 'number of injections' for a higher 'number of injections' when gaining a 6.2% reduction in 'cycle cancellation due to low response', or a 4.5% reduction in 'chance of OHSS'.
  
  
  CONCLUSIONS
  The generalizability of this DCE is limited in time-span. Women may choose differently when they have previous experience with long-acting rFSH, or when they have to pay for the medication, hospital visits and treatments themselves.
  
  
  CONCLUSIONS
  The results of this DCE helps us to understand the trade-off women make in their preference for a long-acting rFSH product or a daily-administrated rFSH product in IVF and may support doctors when counselling patients.
authors.affiliation: Centre for Reproductive Medicine, Academic Medical Centre, Amsterdam, The Netherlands l.vandenwijngaard@amc.nl.
authors.forename: L
authors.initials: L
authors.lastname: van den Wijngaard
authors.affiliation: Centre for Reproductive Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: I C M
authors.initials: IC
authors.lastname: Rodijk
authors.affiliation: Centre for Reproductive Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: van der Veen
authors.affiliation: Department of Obstetrics and Gynaecology, Maxima Medical Centre, Amsterdam, The Netherlands.
authors.forename: M H W
authors.initials: MH
authors.lastname: Gooskens-van Erven
authors.affiliation: Department of Obstetrics and Gynaecology, Maxima Medical Centre, Amsterdam, The Netherlands.
authors.forename: C A M
authors.initials: CA
authors.lastname: Koks
authors.affiliation: Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
authors.forename: H R
authors.initials: HR
authors.lastname: Verhoeve
authors.affiliation: The Robinson Institute, School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, Australia.
authors.forename: B W J
authors.initials: BW
authors.lastname: Mol
authors.affiliation: Centre for Reproductive Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: van Wely
authors.affiliation: Centre for Reproductive Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: M H
authors.initials: MH
authors.lastname: Mochtar
mesh_terms: D000328:Adult; D002755:Choice Behavior; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005307:Fertilization in Vitro / Q000009:adverse effects*; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007247:Infertility, Female / Q000503:physiopathology / Q000628:therapy*; D007279:Injections, Subcutaneous; D016015:Logistic Models; D009426:Netherlands; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects / Q000503:physiopathology; D010062:Ovulation Induction / Q000009:adverse effects*; D010353:Patient Education as Topic; D057240:Patient Preference; D011795:Surveys and Questionnaires
chemical_list: D003692:Delayed-Action Preparations; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide
keywords: IVF; OHSS; discrete choice experiment; long-acting rFSH; patient preference